Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merus N.V. CS
(NQ:
MRUS
)
52.98
+1.35 (+2.61%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merus N.V. CS
< Previous
1
2
Next >
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
September 30, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
September 17, 2024
Petosemtamab in 2L+ HNSCC interim clinical data selected for rapid oral presentation
From
Merus N.V.
Via
GlobeNewswire
Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
August 06, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
August 01, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
July 24, 2024
Petosemtamab 1500 mg Q2W confirmed for both 2/3L phase 3 trial (LiGeR-HN2) and 1L trial (LiGeR-HN1) in r/m HNSCC following FDA feedback
From
Merus N.V.
Via
GlobeNewswire
Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
July 08, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
July 01, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
June 03, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
June 02, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Pricing of Upsized Public Offering of Common Shares
May 29, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
May 29, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus N.V. Announces Proposed Public Offering of Common Shares
May 28, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
May 28, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
May 23, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
May 23, 2024
From
Merus N.V.
Via
GlobeNewswire
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
May 13, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
May 08, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
May 06, 2024
If approved, Zeno will be the first targeted therapy for NRG1+ cancer
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
April 24, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
April 08, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Merus N.V.
Via
GlobeNewswire
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
March 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
March 05, 2024
Poster presentation: Monday, April 8, 2024, 9:00 am-12:30 p.m. PT
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
March 04, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
February 28, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in Upcoming Investor Conferences
January 31, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
December 02, 2023
MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
November 26, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
November 02, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in Upcoming Investor Conferences
November 01, 2023
From
Merus N.V.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.